Latest News about TVTX
Recent news which mentions TVTX
Additional Data From Travere Therapeutics' Kidney Disease Candidate Reinforce Efficacy, Supporting Ongoing Launch
April 03, 2023
Tickers
TVTX
From Benzinga
3 Up-and-Coming Growth Stocks to Buy Right Now
March 25, 2023
From Motley Fool
From Motley Fool
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
March 01, 2023
From Benzinga
From Benzinga
Travere Therapeutics's Return On Capital Employed Overview
February 28, 2023
Tickers
TVTX
From Benzinga
Why Travere Therapeutics Stock Bolted Higher This Week
February 23, 2023
Tickers
TVTX
From Motley Fool
Earnings Scheduled For February 23, 2023
February 23, 2023
From Benzinga
What 10 Analyst Ratings Have To Say About Travere Therapeutics
February 22, 2023
Tickers
TVTX
From Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 21, 2023
From Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 21, 2023
From Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
February 21, 2023
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
From Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
From Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 20, 2023
From Benzinga
From Motley Fool
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Monday
December 12, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
December 05, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Tuesday
November 22, 2022
From Benzinga
Travere Therapeutics Earnings Perspective: Return On Capital Employed
November 03, 2022
Tickers
TVTX
From Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.